论文部分内容阅读
美国FDA已准于可供口服的西那非尔(sildenafil cit-rate,商品名Vidgra,伟哥)用于治疗阳萎,该药属于5型磷酸二酯酶抑制剂,通过改善阴茎血流而起作用。 批准消息一出,生产该药的辉瑞公司的股票立即在交易市场上引起轰动。美国约有三千万男性患有阳萎症,仅以10％的患者打算寻求该药,一年的销售金额就可达到25亿美元。近期欧洲也准于该药上市,市场不断扩大,将给辉瑞带来史无前例的经济效益。
The US FDA has approved the use of oral sildenafil cit-rate (trade name Vidgra, Viagra) for the treatment of impotence, which is a type 5 phosphodiesterase inhibitor that improves blood flow through the penis. effect. As soon as the approval message was announced, Pfizer’s stocks that produced the drug immediately caused a sensation in the trading market. About 30 million men in the United States suffer from impotence. Only 10% of patients plan to seek the drug, and the sales amount in a year can reach 2.5 billion US dollars. In the near future, Europe is also quasi-admitted to the listing of this drug. The continuous expansion of the market will bring unprecedented economic benefits to Pfizer.